| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Chardan Capital analyst Rudy Li initiates coverage on Immunic (NASDAQ: IMUX) with a Buy rating and announces Price Target of...
HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ: IMUX) with a Buy and maintains $10 price target.
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ: IMUX) with a Buy and maintains $10 price target.
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Tria...
Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule the...
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $10 price target.
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by ...
